RDx Bioscience (RDx), formerly Tenet Diagnostics, debuts a new national brand operating in 47 states with expansion of services as a comprehensive laboratory, integrated support of value-based programs and continued leadership in the opioid epidemic.
KENILWORTH, N.J.--(BUSINESS WIRE)--RDx Bioscience (RDx), formerly Tenet Diagnostics, debuts a new national brand operating in 47 states with expansion of services as a comprehensive laboratory, integrated support of value-based programs and continued leadership in the opioid epidemic. Powered by a fast, full-service high-tech laboratory with quick turnaround of test results, RDx is grounded in clinical knowledge, cutting-edge instruments and support, delivering personalized care that improves patient outcomes and transforms the evaluation, monitoring and treatment of illness.
Tenet Diagnostics Unveils New RDx Bioscience Brand: Reason Diagnostics is Fast, Full-Service Laboratory with Clinical Expertise Embracing 21st Century Dx Model @rdxbioscience
“At the intersection of technology, purpose and good health, RDx enables leading providers to better understand and treat the populations they serve, in the quest to help those who are suffering with chronic illnesses and improve individual outcomes,” says Scott Howell, D.O., MPH &TM, CPE, chief medical officer, RDx. “Our new brand better reflects who we are and what we do for our clients, because there is an evidence-based reason behind every test we perform. We are a forward-thinking organization that adopts innovative diagnostics, from routine blood or toxicology testing to the individual genomic testing that is the cornerstone of personalized medicine.”
Dr. Howell explains that diagnostic tests are one of the most important components of medical care, influencing more than 70 percent of health care decisions. Some tests are used for risk assessment purposes—to determine the likelihood that a medical condition is, or will become, present. Others are used to identify disease, to guide the selection of treatments, and to assess a patient’s response to therapy.
“RDx capabilities include sophisticated testing to evaluate the risk of adverse drug reactions and expertise in the synthetic opioid epidemic,” adds Dr. Howell.
Embracing the shift from fee-for-service transactions to value-based diagnostics, RDx identifies necessary life-saving (and cost-slashing) testing, reducing unnecessary tests, empowering client goals to meet the best interests of the patient – driven by purposes of health and recovery, not the number of tests performed. RDx is a developer of the industry’s best practices to optimize results, supporting physicians and providers, payers, employers and patients in every healthcare setting.
“We have the flexibility to customize testing, the expertise to concentrate on the meticulous details of producing precise information that meets physician expectations, and the reliability to turn around fast, accurate tests for the new value-based environment,” Dr. Howell concludes. “Our new corporate brand exemplifies our exceptional vision for the future and reflects the high level of diagnostic services that we deliver.”
About RDx
RDx is a full-service, high-technology laboratory. We are fast, accurate, and deliver value-based service nationally. RDx is accredited by the College of American Pathologists (CAP) as a certified, full-service medical laboratory. Visit http://www.rdxbioscience.com/.
Contacts
Media:
CPR for RDx
Brittany Tedesco
btedesco@cpronline.com
201.641.1911 x14
